Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 2, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 11,636,364 shares of its common stock at a price of $6.60
View HTML
Toggle Summary ImmunoGen Announces Proposed Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 30, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, $175 million of shares of its
View HTML
Toggle Summary ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4% Median Duration of Response at Data Cutoff is 5.9 Months Continued Demonstration of Favorable Tolerability Profile BLA Submission on Track for First Quarter of 2022 Conference Call to be Held at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 24, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on November 22, 2021 the compensation committee of the Company’s Board of Directors granted
View HTML
Toggle Summary ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 17, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Tracey L. McCain , Esq. to its Board of Directors.
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 16, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that in connection with the appointment of Kristen Harrington-Smith as ImmunoGen’s Senior Vice President
View HTML
Toggle Summary ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 16, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Kristen Harrington-Smith has been appointed Senior Vice President and Chief Commercial Officer.
View HTML
Toggle Summary ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
Triplet Demonstrated Manageable Safety Profile and Encouraging Activity, with 55% Objective Response Rate Across All Doses/Schedules in Escalation Data for IMGN632 in Frontline BPDCN Patients Will Also be Presented WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 4, 2021-- ImmunoGen Inc.
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on October 29, 2021 the compensation committee of the Company’s Board of Directors granted a
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
Top-Line Data from Pivotal SORAYA Trial Evaluating Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer on Track for Release this Quarter IMGN632 AML Combination Data to be Highlighted at ASH Annual Meeting PICCOLO, Single-Arm Study of Mirvetuximab in Platinum-Sensitive Ovarian Cancer,
View HTML